A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

March 11, 2024

Conditions

Covid19

Interventions

DRUG

ALLOCETRA-OTS

The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.

OTHER

Placebo

Ringer's lactate solution

Trial Locations (1)

Hadassah Ein Kerem Medical Center, Jerusalem